Genitourinary Drugs Market cover

Genitourinary Drugs Market by Indications (Ovarian Cancer, Prostate Cancer, Bladder Cancer, Renal Cancer, Cervical Cancer, Erectile Dysfunction, Urinary, Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Urinary Tract Infections, Hematuria, and Benign Prostatic Hyperplasia), Products (Hormonal Therapy, Urologicals, Gynecological, Anti-infectives, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: CG-2396
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 4
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global genitourinary drugs market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of genitourinary disorders and increasing number of pipeline drugs.

Genitourinary Drugs Market summary

Genitourinary tract agents are the medicines used to diagnose situations of the excretory system and reproductive organs. These medicines are used to prevent preterm labor, urinary modifiers, and medicines for erectile dysfunction in men. The rising incidence of genitourinary disorders and rising number of pipeline drugs are expected to enlarge the scope for the market. Currently, the wide range of generics and counterfeit launched by large pharmaceutical companies and medium-sized drug manufacturers are presumed to affect the market.

The vast pipeline drugs with a high chance of clearing medical trials in the future is anticipated to perform the market at a rapid pace. Meanwhile, Nektar Therapeutics collaborated with Bristol-Myers Squibb to analyze the coupled efficacy and Opdivo in treating five tumor types, including bladder cancer in September 2016. Moreover, continual patent expirations during the forecast period are presumed to hamper the growth of this sector.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing prevalence of genitourinary disorders is expected to be a key driver for the market growth.  
  • Growing number of pipeline drugs and rapid development of new drugs for the treatment are expected to widen the scope for the market growth in the coming years.
  • High probability of clearing medical trials of drugs in the future is expected to serve as a significant growth driver.
  • Arrival of a wide range of generics and counterfeit launched by big pharmaceutical companies along with the expansion of small and medium scale drug manufacturers are expected to hamper the market growth.
  • Ongoing R&D programs and advancement of technology for the development of drugs are major factors offering massive opportunities for the market expansion in the long run.

Scope of the Report                         

The report on the global genitourinary drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Genitourinary Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Indications (Ovarian Cancer, Prostate Cancer, Bladder Cancer, Renal Cancer, Cervical Cancer, Erectile Dysfunction, Urinary, Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Urinary Tract Infections, Hematuria, and Benign Prostatic Hyperplasia) and Products (Hormonal Therapy, Urologicals, Gynecological, Anti-infectives, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Astellas Pharma US, Inc.; GlaxoSmithKline plc.; Antares Pharma, Inc.; Allergan plc.; Bayer AG; Eli Lilly and Company; Merck KGaA; Bristol-Myers Squibb Company; Abbott Healthcare; Genentech USA, Inc.; Novartis International AG; Teva Pharmaceutical Industries Ltd.; F. Hoffman-La Roche AG; Astrazeneca Pharma India Ltd; Pfizer Inc.; and Advanz Pharma Corp.

Market Segment Insights

Prostate cancer segment is expected to grow at a rapid pace

Based on indications, the global genitourinary drugs market is divided into ovarian cancer, prostate cancer, bladder cancer, renal cancer, cervical cancer, erectile dysfunction, urinary, incontinence & overactive bladder, sexually transmitted diseases, interstitial cystitis, urinary tract infections, hematuria, and benign prostatic hyperplasia. The prostate cancer segment is expected to grow at a rapid pace during the forecast period owing to wide range of available therapeutic of the particular disease type. However, the hematuria segment is anticipated to expand at a robust growth rate during the forecast period due to large investment on R&D by key market players.

Gynecological segment is projected to expand at a considerable CAGR

On the basis of products, the market is divided into hormonal therapy, urologicals, gynecological, anti-infectives, and others. The gynecological segment is projected to expand at a considerable CAGR during the forecast period owing to presence of wider product range for reproductive disorders. Meanwhile, the hormonal therapy segment is attributed to account for a key market share during the projected period due to advancement in technology.

Genitourinary Drugs Market product

North America is anticipated to constitute a key market share

In terms of regions, the global genitourinary drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years due to high prevalence of huge genitourinary diseases in this region. The market of Asia Pacific, however, is anticipated to exhibit substantial growth during the forecast period owing to continual improvements in healthcare infrastructure and growing awareness among people of these emerging economies in the region.

Genitourinary Drugs Market region

Segments

Segments Covered in the Report

The global genitourinary drugs market has been segmented on the basis of

Indications

  • Ovarian Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Renal Cancer
  • Cervical Cancer
  • Erectile Dysfunction
  • Urinary
  • Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Urinary Tract Infections
  • Hematuria
  • Benign Prostatic Hyperplasia

Products

  • Hormonal Therapy
  • Urologicals
  • Gynecological
  • Anti-infectives
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Astellas Pharma US, Inc.
  • GlaxoSmithKline plc
  • Antares Pharma, Inc.
  • Allergan plc
  • Bayer AG
  • Eli Lilly and Company
  • Merck KGaA
  • Bristol-Myers Squibb Company
  • Abbott Healthcare
  • Genentech USA, Inc.
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffman-La Roche AG
  • Astrazeneca Pharma India Ltd
  • Pfizer Inc.
  • Advanz Pharma Corp.

Competitive Landscape

Key players competing in the global genitourinary drugs market are Astellas Pharma US, Inc.; GlaxoSmithKline plc; Antares Pharma, Inc.; Allergan plc; Bayer AG; Eli Lilly and Company; Merck KGaA; Bristol-Myers Squibb Company; Abbott Healthcare; Genentech USA, Inc.; Novartis International AG; Teva Pharmaceutical Industries Ltd.; F. Hoffman-La Roche AG; Astrazeneca Pharma India Ltd; Pfizer Inc.; and Advanz Pharma Corp. The main market players are continuously engaged in various business development strategies such as mergers and acquisitions, research and developments, investments for innovative products and collaborations. Genentech, Inc. received the US FDA approval for its product, Tecentriq to treat patients suffering from bladder cancer in May 2016.

Genitourinary Drugs Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genitourinary Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Genitourinary Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Genitourinary Drugs Market - Supply Chain
  4.5. Global Genitourinary Drugs Market Forecast
     4.5.1. Genitourinary Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Genitourinary Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Genitourinary Drugs Market Absolute $ Opportunity
5. Global Genitourinary Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Genitourinary Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Genitourinary Drugs Demand Share Forecast, 2019-2026
6. North America Genitourinary Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Genitourinary Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Genitourinary Drugs Demand Share Forecast, 2019-2026
7. Latin America Genitourinary Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Genitourinary Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Genitourinary Drugs Demand Share Forecast, 2019-2026
8. Europe Genitourinary Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Genitourinary Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Genitourinary Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Genitourinary Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Genitourinary Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Genitourinary Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Genitourinary Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Genitourinary Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Genitourinary Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Genitourinary Drugs Market: Market Share Analysis
  11.2. Genitourinary Drugs Distributors and Customers
  11.3. Genitourinary Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Astellas Pharma US, Inc.
     11.4.2. GlaxoSmithKline plc
     11.4.3. Antares Pharma, Inc.
     11.4.4. Allergan plc
     11.4.5. Bayer AG
     11.4.6. Eli Lilly and Company
     11.4.7. Merck KGaA
     11.4.8. Bristol-Myers

Segments Covered in the Report

The global genitourinary drugs market has been segmented on the basis of

Indications

  • Ovarian Cancer
  • Prostate Cancer
  • Bladder Cancer
  • Renal Cancer
  • Cervical Cancer
  • Erectile Dysfunction
  • Urinary
  • Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Urinary Tract Infections
  • Hematuria
  • Benign Prostatic Hyperplasia

Products

  • Hormonal Therapy
  • Urologicals
  • Gynecological
  • Anti-infectives
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Astellas Pharma US, Inc.
  • GlaxoSmithKline plc
  • Antares Pharma, Inc.
  • Allergan plc
  • Bayer AG
  • Eli Lilly and Company
  • Merck KGaA
  • Bristol-Myers Squibb Company
  • Abbott Healthcare
  • Genentech USA, Inc.
  • Novartis International AG
  • Teva Pharmaceutical Industries Ltd.
  • F. Hoffman-La Roche AG
  • Astrazeneca Pharma India Ltd
  • Pfizer Inc.
  • Advanz Pharma Corp.

Key players competing in the global genitourinary drugs market are Astellas Pharma US, Inc.; GlaxoSmithKline plc; Antares Pharma, Inc.; Allergan plc; Bayer AG; Eli Lilly and Company; Merck KGaA; Bristol-Myers Squibb Company; Abbott Healthcare; Genentech USA, Inc.; Novartis International AG; Teva Pharmaceutical Industries Ltd.; F. Hoffman-La Roche AG; Astrazeneca Pharma India Ltd; Pfizer Inc.; and Advanz Pharma Corp. The main market players are continuously engaged in various business development strategies such as mergers and acquisitions, research and developments, investments for innovative products and collaborations. Genentech, Inc. received the US FDA approval for its product, Tecentriq to treat patients suffering from bladder cancer in May 2016.

Genitourinary Drugs Market keyplayers

Buy Report